What is the management for a patient with asthma exacerbation, who has wheezing, normal oxygen (O2) saturation, and a peak expiratory flow of 60% of predicted, after taking two puffs of salbutamol (albuterol) at home?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Asthma Exacerbation with PEF 60%

Give salbutamol with a spacer (up to 20 puffs) and reassess in 15-30 minutes before considering ipratropium. 1

Severity Classification

This patient presents with moderate asthma exacerbation, not acute severe asthma, based on the following assessment 1, 2:

  • Able to speak in sentences (not just words) - indicates NOT severe
  • PEF 60% (above the 50% threshold for severe asthma)
  • Normal oxygen saturation (no hypoxemia)
  • Wheezing present but no silent chest

The British Thoracic Society defines acute severe asthma as requiring **PEF <50% predicted or best**, inability to complete sentences, pulse >110 bpm, or respirations >25/min 1, 2. This patient does not meet these criteria.

Initial Management Approach

First-Line Treatment

Administer additional salbutamol via MDI with spacer 1:

  • Give 2 puffs every few seconds up to maximum 20 puffs total if no nebulizer available 1
  • This approach is as effective as nebulized beta-agonists in moderate exacerbations 1, 3
  • The patient has only taken 2 puffs at home, which is insufficient dosing for an acute exacerbation

Reassessment Protocol

Monitor response at 15-30 minutes after salbutamol administration 1, 4:

  • Remeasure peak expiratory flow
  • Reassess symptoms and vital signs
  • Determine if PEF improves to >75% predicted (can step up usual treatment) or remains 50-75% (needs systemic corticosteroids)

When to Add Ipratropium

Ipratropium is NOT first-line for moderate exacerbations 1, 2. Add ipratropium only if:

  • Features of acute severe asthma persist after initial beta-agonist treatment (PEF remains <50%) 1
  • Life-threatening features develop 2
  • Patient requires hospital admission 1, 4

The British Thoracic Society specifically recommends adding ipratropium for severe attacks or when severe features persist after initial treatment, not as immediate first-line therapy 1, 2.

Additional Management

Systemic Corticosteroids

Administer prednisolone 30-60 mg orally if PEF remains 50-75% after bronchodilator treatment 1, 4:

  • Corticosteroids should be given within the first hour for moderate-to-severe exacerbations 4, 3
  • Continue for minimum 5 days, typically 5-10 days total 2, 4

Follow-Up Requirements

Arrange review within 48 hours for moderate exacerbations 2:

  • Monitor symptoms and PEF on chart 1
  • Provide written self-management plan 2
  • Verify inhaler technique 5
  • Step up maintenance therapy as needed 1

Common Pitfalls to Avoid

  • Do not immediately jump to ipratropium - this patient needs adequate beta-agonist dosing first 1
  • Do not underestimate severity - while this is moderate, failure to respond requires escalation 1, 5
  • Do not discharge without reassessment - response to treatment must be documented before leaving 1
  • Lower threshold for admission if symptoms worsen in afternoon/evening, recent nocturnal symptoms, or previous severe attacks 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Acute Asthma Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Management of acute asthma exacerbations.

American family physician, 2011

Guideline

Management of Asthma Exacerbation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Asthma Management Monitoring and Follow-Up

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.